Abstract TH818: Associations of Glycemic Control and Diabetes Duration With Incident Dementia: The Atherosclerosis Risk in Communities Neurocognitive Study (ARIC-NCS)

J Jason Smith A A Sharrett (JOHN HOPKINS UNIV, Baltimore, Maryland, United States) P Priya Palta (UNC Chapel Hill, Chapel Hill, North Carolina, United States) J Jiaqi Hu E Elizabeth Selvin (Johns Hopkins Bloomberg School of Public Health, Baltimore) J James Pike (Johns Hopkins University, Chapel Hill, North Carolina, United States) R Rebecca Gottesman (NINDS, Bethesda, Maryland, United States) P Pamela Lutsey (University of Minnesota, Minneapolis, Minnesota, United States) B B Gwen Windham (UMMC, The MIND Center, Jackson, Mississippi, United States) D David Knopman J Joe Coresh (New York University Grossman School of Medicine, New York, New York, United States) A Alden Gross (JOHNS HOPKINS UNIVERSITY, Baltimore, Maryland, United States) J Jennifer Deal (Johns Hopkins University, Baltimore, Maryland, United States)

Abstract

Introduction: Diabetes, a modifiable risk factor for dementia, is thought to impart increased risk of dementia through cerebral small vessel disease. While the importance of diabetes in midlife is well-documented, the influence of different glycemic levels, duration of diabetes, and Alzheimer’s disease genetic risk (apolipoprotein [ APOE ] ε4 genotype) in late-life on dementia risk remains uncertain. This could have implications for individualized prevention strategies. In this study, we investigated whether a higher glycemic level and longer duration of diabetes in late-life is associated with a higher risk of dementia, and whether associations vary by APOE ε4 genotype. Methods: We performed a prospective cohort analysis with the Atherosclerosis Risk in Communities Study using up to 11 years of follow-up (baseline, 2011-2013). We defined diabetes as glycated hemoglobin A1c (HbA 1c ) ≥6.5%, self-reported physician diagnosis, or use of any diabetes medication. Among those with diabetes, we categorized participants as having a lower glycemic level (HbA 1c <7%) or higher level (HbA 1c ≥7%), and duration as short (<5 years) or long (≥5 years). We estimated hazard ratios (HR) for incident dementia by HbA 1c levels and by diabetes duration in separate multivariable-adjusted Cox regression models. We tested for statistical multiplicative interaction on the relative risk of dementia by fitting interaction terms between diabetes measures and APOE ε4 genotype in separate regression models. Results: In 5030 participants without dementia (mean age, 75.4 years; 58.6% female; 21% Black; 28% with diabetes), there were 1167 (23.2%) incident dementia cases over a median follow-up of 9.0 years. Compared to no diabetes, a lower glycemic level and higher level were both associated with elevated dementia risk ( P -trend <.0001; Table). A higher glycemic level was associated with an elevated risk of dementia relative to a lower level (HR=1.47 [95% CI: 1.22-1.77]; Table). Compared to no diabetes, both shorter duration and longer duration were associated with an increase in dementia risk ( P -trend <.0001; Table). Longer duration was associated with an increased risk of dementia relative to shorter duration (HR=1.57 [95% CI: 1.24-1.98]; Table). Associations for glycemic level and diabetes duration did not significantly differ by APOE ε4 genotype (all P >.05). Conclusions: Diabetes management in older adults that includes lower glycemic goals may help reduce dementia risk.

Article Details

Journal Circulation
Volume / Issue Vol. 153, Issue Suppl_1
Published March 24, 2026
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (13)

J

Jason Smith

A

A Sharrett

JOHN HOPKINS UNIV, Baltimore, Maryland, United States

P

Priya Palta

UNC Chapel Hill, Chapel Hill, North Carolina, United States

J

Jiaqi Hu

E

Elizabeth Selvin

Johns Hopkins Bloomberg School of Public Health, Baltimore

J

James Pike

Johns Hopkins University, Chapel Hill, North Carolina, United States

R

Rebecca Gottesman

NINDS, Bethesda, Maryland, United States

P

Pamela Lutsey

University of Minnesota, Minneapolis, Minnesota, United States

B

B Gwen Windham

UMMC, The MIND Center, Jackson, Mississippi, United States

D

David Knopman

J

Joe Coresh

New York University Grossman School of Medicine, New York, New York, United States

A

Alden Gross

JOHNS HOPKINS UNIVERSITY, Baltimore, Maryland, United States

J

Jennifer Deal

Johns Hopkins University, Baltimore, Maryland, United States